INCYIncyte CorporationSigning up patients
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 466 (planned)
- Started
- Dec 9, 2025
- Main results expected
- Nov 15, 2028
- Fully finished
- May 14, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) by BICR
Measured over: Up to 2 years
Overall Survival (OS)
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07214779 · record last updated 2026-10-15 · checked 2026-11-09 15:42 UTC